Skip to content

Study · Measured the body's own peptide · 2024

1 result

Weekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial.

Reyes ML, Vizcaya C, Le Roy C, Loureiro C, Brinkmann K, Arancibia M, Campos L, Iturriaga C, Pérez-Mateluna G, Rojas-McKenzie M, Domínguez G, Camargo CA Jr, Borzutzky A

The Journal of pediatrics22 Aug 2024Cited by 9 (Europe PMC)

PMID39181322 (opens in a new tab)DOI10.1016/j.jpeds.2024.114249 (opens in a new tab)PepBankPUB-39181322
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelRandomized controlled trialOther

    In children aged 1.5-3.5 years given weekly vitamin D3 or placebo for 6 months, the change in LL‑37/cathelicidin levels did not differ between groups.

    In plain wordsIn young children, weekly vitamin D did not change the body's own LL‑37 levels compared with placebo.

    Peptide
    LL-37
    Outcome
    No significant changeChange in LL-37/cathelicidin levels after weekly vitamin D3
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    no group differences were observed in number of ARI (P = .85), ARI hospitalizations (P = .20), LL-37/cathelicidin change (P = .30), or adverse events (P = .41)
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial in 303 children aged 1.5-3.5 years
    Summary · context
    secondary outcomes included number of ARI hospitalizations, change of serum 25-hydroxyvitamin D (25(OH)D) and LL-37/cathelicidin levels

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.